U.S. Patent No.
7,148,041 (Animal Product Free Media and Processes for Obtaining a Botulinum Toxin)

Patent Owner
Allergan, Inc.

Petitioner(s)
Galderma S.A.; Galderma Labs, LP; Galderma Labs, Inc.; Galderma R&D, SNC; Nestle Skin Health, Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Manufacturing

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Manufacturing

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

IPR Status
Final Written Decision (Adverse Judgment in Favor of Petitioner for Patent Owner Failure to Respond)

U.S. Patent No.
10,143,728 (Long Lasting Effect of New Botulinum Toxin Formulations)

Patent Owner
Medy-Tox Inc.; AbbVie Inc.; Allergan, Inc.; Allergan Pharmaceuticals Holding; Allergan Pharmaceuticals Ireland

Petitioner(s)
Galderma S.A.; Galderma Labs, LP; Galderma Labs, Inc.; Galderma R&D, SNC; Galderma Skin Health SA; Nestle SA; SHDS, Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
22-1165

IPR Status
Challenges Also Include Enablement, Written Description, and Indefiniteness. FWD (Non-Contingent MTA Denied); Request for Director Review or Panel Rehearing Denied; Federal Circuit Appeal: USPTO Director Intervened, Decision Affirmed